Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum
- PMID: 15155189
- PMCID: PMC415629
- DOI: 10.1128/AAC.48.6.1989-1992.2004
Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum
Abstract
The possible reactivities of commonly used antibiotics of fungal, nonfungal, and nonmicrobial or synthetic sources with the Platelia Aspergillus galactomannan assay were assessed. For drugs that tested positive, the minimal concentration of the antibiotic in serum that yielded a positive test (index, >0.5) was determined. At undiluted concentrations, piperacillin and multiple lots of piperacillin-tazobactam tested positive, whereas amoxicillin, ampicillin-sulbactam, nafcillin, cefazolin, ceftazidime, erythromycin, gentamicin, and levofloxacin tested negative. All three lots of piperacillin-tazobactam and all bags within each lot tested positive, with a mean index value of 5.168. At achievable concentrations in serum, however, only one of three lots of piperacillin-tazobactam yielded a positive test. Concentrations of 75, 150, and 300 microg/ml of serum tested positive with the Platelia Aspergillus enzyme immunoassay, whereas lower concentrations, mimicking the trough levels, tested negative. Thus, while achievable serum piperacillin-tazobactam concentrations may potentially result in a positive test for galactomannan, the timing of the collection of serum samples from patients may influence the test results, with reactivity being less likely in samples collected at trough levels or prior to the administration of a dose of the antibiotic.
Similar articles
-
Drug-laboratory interaction between beta-lactam antibiotics and the galactomannan antigen test used to detect mould infections.Braz J Infect Dis. 2014 Sep-Oct;18(5):544-7. doi: 10.1016/j.bjid.2014.03.009. Epub 2014 May 13. Braz J Infect Dis. 2014. PMID: 24833197 Free PMC article.
-
Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market.Braz J Infect Dis. 2009 Oct;13(5):353-5. doi: 10.1590/S1413-86702009000500007. Braz J Infect Dis. 2009. PMID: 20428634
-
The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections.Infection. 2010 Jun;38(3):217-21. doi: 10.1007/s15010-010-0003-6. Epub 2010 Mar 17. Infection. 2010. PMID: 20237947
-
Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.J Antimicrob Chemother. 1993 Jan;31 Suppl A:29-38. doi: 10.1093/jac/31.suppl_a.29. J Antimicrob Chemother. 1993. PMID: 8383654 Review.
-
Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.Pharmacotherapy. 2000 Sep;20(9 Pt 2):213S-218S; discussion 224S-228S. doi: 10.1592/phco.20.14.213s.35045. Pharmacotherapy. 2000. PMID: 11001328 Review.
Cited by
-
Galactomannan in piperacillin-tazobactam: how much and to what extent?Antimicrob Agents Chemother. 2005 Sep;49(9):3984-5. doi: 10.1128/AAC.49.9.3984-3985.2005. Antimicrob Agents Chemother. 2005. PMID: 16127090 Free PMC article. No abstract available.
-
Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments.J Clin Microbiol. 2005 Oct;43(10):5214-20. doi: 10.1128/JCM.43.10.5214-5220.2005. J Clin Microbiol. 2005. PMID: 16207986 Free PMC article.
-
Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis.Mycopathologia. 2007 Apr;163(4):191-202. doi: 10.1007/s11046-007-9010-2. Epub 2007 Apr 5. Mycopathologia. 2007. PMID: 17410480 Review.
-
Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections.J Clin Microbiol. 2005 Dec;43(12):5957-62. doi: 10.1128/JCM.43.12.5957-5962.2005. J Clin Microbiol. 2005. PMID: 16333082 Free PMC article.
-
Pulmonary aspergillosis: a clinical review.Eur Respir Rev. 2011 Sep 1;20(121):156-74. doi: 10.1183/09059180.00001011. Eur Respir Rev. 2011. PMID: 21881144 Free PMC article. Review.
References
-
- Adam, O., A. Auperin, F. Wilquin, J.-H. Bourhis, B. Gachot, and E. Chachaty. 2004. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin. Infect. Dis. 38:917-920. - PubMed
-
- Ansorg, R., R. van den Boom, and P. M. Rath. 1997. Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses 40:353-357. - PubMed
-
- Fortun, J. P., P. Martin-Davila, S. Moreno, E. de Vicente, J. Nuno, A. Candelas, R. Barcena, and M. Garcia. 2002. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 8:1065-1070. - PubMed
-
- Husain, S., E. J. Kwak, A. Obman, M. M. Wagener, S. Kusne, J. Stout, K. McCurry, and N. Singh. 2004. Prospective assessment of Platelia Aspergillus galactomannan for the diagnosis of invasive aspergillosis in lung transplant recipients. Am. J. Transplant. 4:1-7. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical